Teicoplanin

Hypersensitivity.

Patient with known hypersensitivity or history of neutropenic reaction to vancomycin. Renal impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Closely monitor CBC with differential and platelet count; serum teicoplanin trough concentrations at steady state after the loading dose regimen and at least once weekly during maintenance treatment. Monitor LFTs periodically (prolonged use); renal and auditory function regularly (especially during long-term use or high loading doses in patients with renal impairment). Closely assess for signs of serious skin reactions and hearing impairment.

Significant: Haematologic effects (e.g. thrombocytopenia, neutropenia), hepatotoxicity, ototoxicity (e.g. tinnitus, deafness), nephrotoxicity (e.g. renal failure); bacterial or fungal superinfection (prolonged-use), including Clostridioides difficile-associated diarrhoea and pseudomembranous colitis. Rarely, infusion-related reactions or red man syndrome manifested as pruritus, urticaria, erythema, flushing of the upper body, hypotension, dyspnoea, tachycardia, and angioedema (due to rapid IV inj). Blood and lymphatic system disorders: Agranulocytosis, pancytopenia, leucopenia, eosinophilia. Ear and labyrinth disorders: Vestibular disorder, vertigo. Gastrointestinal disorders: Diarrhoea, vomiting, nausea. General disorders and administration site conditions: Fever, chills, inj site reactions (e.g. pain, erythema, inflammation, abscess). Investigations: Increased serum creatinine, serum transaminases, and blood alkaline phosphatase. Nervous system disorders: Headache, dizziness. Respiratory, thoracic and mediastinal disorders: Bronchospasm. Vascular disorders: Phlebitis.
Potentially Fatal: Severe cutaneous reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis; severe hypersensitivity reactions (e.g. anaphylactic shock).

Increased risk of nephrotoxic or ototoxic effects with aminoglycosides, colistin, amphotericin B, ciclosporin, cisplatin, furosemide, and etacrynic acid.

Other Antibiotics

J01XA02 - teicoplanin ; Belongs to the class of glycopeptide antibacterials. Used in the systemic treatment of infections.